Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
Diabetes, Obesity and Metabolism Feb 20, 2018
Ray KR, et al. - Researchers compared alirocumab (a proprotein convertase subtilisin-kexin type 9 inhibitor) with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally-tolerated statins. Alirocumab showed superiority in non-high-density lipoprotein cholesterol (non-HDL-C) reduction vs UC in individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin. This treatment was generally well tolerated.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
